Top Story
Rough Road Ahead for Innovation
With the continuing attacks on industry pricing and marketing practices, the last few months have been tough for pharmaceutical companies — and the political environment in Washington isn't likely to improve in the coming year, writes Jill Wechsler
...Read more |
 |
Regulatory
Priority Review Vouchers Raise Risks, Say FDA
The FDA program that encourages biopharma companies to develop new treatments for rare and neglected diseases has been in the spotlight recently
...Read more |
 |
North America
Market Access Outlook for Canada
Canada remains the ninth largest pharmaceutical market in the world, but drugmakers may find it increasingly difficult to capitalize on its potential for a number of reasons. Michael J. Kuchenreuther reports
...Read more |
In this paper, IMS Health describes the next generation of sales, marketing and technology - Orchestrated Customer Engagement (OCE). OCE seamlessly marshals the sequence, context, and purpose of messages to multiple influencing stakeholders.
 Learn More
|
Latin America
Colombia: Portage to Latin America?
As an entry port to Latin America from North America, Europe, or Asia, Colombia's geographical positioning makes clear sense for accessing a region that seems remote and exotic. Casey McDonald visits with industry and regulatory officials in Bogotá to discuss Colombia’s strategy for growing its life sciences enterprise
...Read more |
AmerisourceBergen
Patient-Centric Approach to Product Commercialization. In order for the patient to emerge center stage in a commercial approach, it's necessary for manufacturers to shift prioritization's to help the greatest number of patients gain access and remain on treatments. This requires aligning both R&D and marketing efforts with patient needs in order to drive positive outcomes — clinical as well as behavioral. The result is a successful product with far greater commercial value in a crowded and highly competitive market.
 Click here for more information.
|
 |
 //Galena Biopharma (San Ramon, CA) announced that Steven A. Kriegsman has decided to retire as a director of the company when his current term expires the day prior to the June 2016 Annual Meeting of Stockholders.//Caladrius Biosciences (Basking Ridge, NJ) appointed Steven S. Myers, previously the Board's lead independent director, as interim Chairman of the Board, subsequent to the resignation of Robin L. Smith, M.D, as Chairman of the Board and a Director.//
|
|
|
|
|
